Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 27 recruiting now early-phase tilt #96 of 28,707 conditions

Smoking: early-phase trial registry

27 of 124 indexed Smoking trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #96 of 28,707 conditions by registered trial count.

124 US clinical trials · 27 currently recruiting · #96 of 28,707 conditions by registered trial count

Smoking: 124 US clinical trials tracked, 27 recruiting.

Smoking is the subject of 124 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is RAI Services Company, running 9 of these trials.

Enrollment posture brief

Registry condition smoking

OPEN 27 | RECR 22% | LATE 13 | EARLY 22 | RANK #96 | SPON 9

Nearest open-share peer: Plaque Psoriasis (22% recruiting · 46 trials)

Head and Neck Squamous Cell 56.8%Advanced Cancer36.6%Ulcerative Colitis36.6%Low Back Pain25.2%Smoking (this)22%
Open-enrollment share among volume-matched conditions near Smoking

Smoking lists 27 open slots (22% of 124 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Smoking on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Smoking is recruiting below its size-band peers.

    27 of 124 indexed trials (21.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Smoking trials is spread across many organizations.

    RAI Services Company accounts for 9 of 124 trials (7.3%). 62 distinct sponsors appear on at least one study for this condition label.

  3. Typical Smoking enrolment sits around 165 participants.

    Median target enrolment is 165 among the 124 trials that report a genuine target (sentinel values excluded). 48 of those (38.7%) plan for fewer than 100 participants.

  4. Smoking research is mostly interventional.

    113 interventional and 11 observational studies make up this index (91.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 19Phase 213Phase 34Phase 49

Open and recent trials

124 total, page 3 of 3

COMPLETED Early Phase 1 50 participants

Combination SBIRT for Emergency Department Patients Who Drink and Smoke

Yale University

NCT01595178

COMPLETED NA 49 participants

Tumor Markers in Lung Cancer: DCAMLK-1LK-1

University of Oklahoma

NCT01578018

COMPLETED 44 participants

Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics

University of North Carolina, Chapel Hill

NCT01663298

COMPLETED 42 participants

Integrative-omics of the Disordered COPD Small Airway Epithelium

Weill Medical College of Cornell University

NCT02183818

COMPLETED NA 42 participants

CSD201301: Study to Assess Elements of Abuse Liability for Four P13 Nicotine Pouches

RAI Services Company

NCT05294497

COMPLETED NA 41 participants

Effects of Smoking Environment on Craving and Smoking

Duke University

NCT02416986

COMPLETED NA 40 participants

Modern Nicotine Oral Product Abuse Liability

RAI Services Company

NCT06777784

COMPLETED NA 40 participants

Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents (smokeScreen)

Yale University

NCT03722888

COMPLETED NA 40 participants

Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery

Dartmouth-Hitchcock Medical Center

NCT04481737

COMPLETED Phase 1 40 participants

A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers

GlaxoSmithKline

NCT01702519

COMPLETED NA 37 participants

Acute Effects of TCIG vs ECIG in PLWH

University of California, Los Angeles

NCT04568395

COMPLETED NA 36 participants

CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12

RAI Services Company

NCT05239884

COMPLETED NA 33 participants

Electronic Hookah and Endothelial Cell Function

University of California, Los Angeles

NCT04133376

COMPLETED NA 31 participants

Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking

Medical University of South Carolina

NCT03311646

COMPLETED Phase 2 30 participants

The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse

Yale University

NCT00773422

COMPLETED NA 24 participants

Salt-Based E-cigarette

Medical University of South Carolina

NCT04238832

COMPLETED NA 22 participants

Randomized Pilot Study of a mHealth App for Ambivalent Smokers Living With HIV

Kaiser Permanente

NCT05339659

COMPLETED NA 21 participants

Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free

H. Lee Moffitt Cancer Center and Research Institute

NCT05362318

COMPLETED NA 21 participants

BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability

RAI Services Company

NCT06105424

COMPLETED NA 19 participants

Sensory Perception of Sweet Flavors in E-Cigarette

Oregon State University

NCT03332953

COMPLETED NA 18 participants

E-cigarette Nicotine Pharmacokinetic Study

British American Tobacco (Investments) Limited

NCT03178981

COMPLETED NA 17 participants

E-cigarettes for Harm Reduction in Adults With Asthma

Brown University

NCT05278065

COMPLETED Phase 1 12 participants

Galantamine Effects on Nicotine Responses in Smokers

Yale University

NCT01417429

COMPLETED NA 11 participants

A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis

Northwell Health

NCT01399112

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 13
Phase 3 4
Phase 4 9

Named interventions

Most-linked intervention names on Smoking records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Product D Other
4 trials
Product C Other
4 trials
Product B Other
4 trials
Nicotine Patch Drug
4 trials
Product A Other
3 trials
varenicline Drug
2 trials
Product E Other
2 trials

US sites by state

Facility locations filed on Smoking trials. A trial with sites in several states counts in each.

New York 16 trials
Texas 14 trials
California 10 trials
Washington 9 trials
South Carolina 9 trials
Minnesota 9 trials
Pennsylvania 8 trials
Oregon 8 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Smoking page

124 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Smoking condition card totals 124 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.